The effect of gastric <i>Helicobacter pylori</i> eradication on recurrent aphthous stomatitis

Karaca, Şemsettin; Seyhan, Muammer; Şenol, Mustafa; Harputluoğlu, Murat; Özcan, Atilla

doi:10.1111/j.1365-4632.2008.03667.x

Cited by 29 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…H. pylori infections were identified in the oral tissue by polymerase chain reaction (PCR) in a small proportion of RAS cases (12). Furthermore, H. pylori eradication may lead to fewer recurrences and longer RAS disease-free intervals (13,14).…”

Section: Introductionmentioning

confidence: 99%

The relationship of recurrent aphthous stomatitis and Helicobacter pylori, cytokine gene polymorphism and cobalamin

Yakar

Serin²,

Am³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: The aim of the present study was to investigate whether Helicobacter pylori causes or triggers recurrent aphthous stomatitis (RAS) through cytokine gene polymorphism and/or cobalamin deficiency. Materials and Methods: Thirty-six patients with RAS and 130 patients without RAS were genotyped for IL-1β (−511C/T) and IL-6 (−174G/C) and evaluated for H. pylori infection and serum cobalamin level. Results: The patient groups according to RAS had similar rates of H. pylori gastritis and interleukin genotypes/alleles, and there was a non-significant difference between serum cobalamin levels (p>0.05). RAS patients with H. pylori gastritis showed a higher frequency (51.9%) of GC IL-6 genotype than RAS patients without H. pylori gastritis (11.1%) (p=0.036). Non-GG genotype and C allele were increased in patients without RAS and with H. pylori gastritis (p<0.05). Patients with H. pylori gastritis showed a lower value of serum cobalamin without statistical significance, although this difference was more prominent in RAS patients (p=0.07). Conclusion: The carriage of the C allele of IL-6 may lead a susceptibility to chronic gastric inflammation after contamination with H. pylori. If H. pylori infection is justified as a predisposing factor for RAS and its severity by further studies, we can speculate that subjects with genetic susceptibility to this infection may benefit from H. pylori eradication treatment with respect to RAS.

show abstract

Section: Introductionmentioning

confidence: 99%

The relationship of recurrent aphthous stomatitis and Helicobacter pylori, cytokine gene polymorphism and cobalamin

Yakar

Serin²,

Am³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Similarly, the palatine tonsil represents an extragastric reservoir of H. pylori that facilitates its oral transmission. A study of 23 patients with recurrent aphthous stomatitis showed a significant reduction in recurrence and amelioration time after eradication 101 …”

Section: Extraintestinal Diseasesmentioning

confidence: 99%

Future candidates for indications of Helicobacter pylori eradication: Do the indications need to be revised?

Lee

2012

J of Gastro and Hepatol

View full text Add to dashboard Cite

Since the discovery of Helicobacter pylori in 1982, the development of several treatment guidelines has allowed a consensus on the indications for H. pylori eradication. Beyond these currently accepted indications, including various upper gastrointestinal disorders and extragastric diseases, a significant amount of new information regarding H. pylori eradication is emerging. Certain types of acute gastritis, such as nodular gastritis, hypertrophic gastritis, Ménétrier's disease, hemorrhagic gastritis, and granulomatous gastritis are reversible after H. pylori eradication. Further, for chronic gastritis, closed-type atrophic gastritis and complete-type intestinal metaplasia appear to be more reversible after H. pylori eradication than open-type atrophic gastritis and incomplete-type intestinal metaplasia. Eradication can also be considered in subjects younger than 40 years who have a family history of gastric cancer and in subjects with long-term medications that might lead to bleeding (antiplatelet agents) or atrophy (proton pump inhibitors). Emerging evidence indicates that H. pylori eradication could be an effective treatment for some extragastric diseases that are unresponsive to conventional therapy. In such conditions, routine screening for eradication of H. pylori has not previously been recommended; a "test-and-treat" approach is suggested in the aforementioned situations. Given that H. pylori eradication is effective when the gastritis is reversible, future indications should be expanded to include acute gastric lesions that show marked improvement upon H. pylori eradication rather than just focusing on chronic gastric lesions. Future indications for H. pylori eradication should focus more on reversible lesions before preneoplastic conditions develop.

show abstract

“…There have been many researches to determine the causes of RAS. Genetic, immunologic, infectious factors as well as local and systemic conditions have all been implicated as potential etiopathogenic agents (Kewkowicz et al , 2003; Lin et al , 2005; Karaca et al , 2008). However, to date, no principal etiology has been discovered.…”

Section: Introductionmentioning

confidence: 99%

Oxidant/antioxidant status in recurrent aphthous stomatitis

et al. 2009

View full text Add to dashboard Cite

show abstract

The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis

Abstract: We concluded that eradication of H. pylori may have reducing effects on the recurrence and amelioration period of the RAS.

Cited by 29 publications

References 13 publications

The relationship of recurrent aphthous stomatitis and Helicobacter pylori, cytokine gene polymorphism and cobalamin

The relationship of recurrent aphthous stomatitis and Helicobacter pylori, cytokine gene polymorphism and cobalamin

Future candidates for indications of Helicobacter pylori eradication: Do the indications need to be revised?

Oxidant/antioxidant status in recurrent aphthous stomatitis

Contact Info

Product

Resources

About